ECSP089019A - Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa - Google Patents

Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa

Info

Publication number
ECSP089019A
ECSP089019A EC2008009019A ECSP089019A ECSP089019A EC SP089019 A ECSP089019 A EC SP089019A EC 2008009019 A EC2008009019 A EC 2008009019A EC SP089019 A ECSP089019 A EC SP089019A EC SP089019 A ECSP089019 A EC SP089019A
Authority
EC
Ecuador
Prior art keywords
fusioned
sulfonamide inhibitors
tricyclic sulfonamide
secret range
secret
Prior art date
Application number
EC2008009019A
Other languages
English (en)
Inventor
Roy Hom
Andrei Konradi
Christopher M Semko
Albert W Garofalo
Gary Probst
Danielle L Aubele
Martin L Neitzel
Anh P Truong
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of ECSP089019A publication Critical patent/ECSP089019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

La invención provee los compuestos de Fórmula I: o sus sales farmacéuticamente aceptables, donde R1, R2 y donde los anillos A, B y C son tal como se definen. La invención también provee composiciones farmacéuticas que comprenden compuestos o sales de la fórmula (I), métodos para preparar dichos compuestos.
EC2008009019A 2006-06-02 2008-12-29 Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa ECSP089019A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81043106P 2006-06-02 2006-06-02
US87693206P 2006-12-22 2006-12-22
US92277107P 2007-04-10 2007-04-10

Publications (1)

Publication Number Publication Date
ECSP089019A true ECSP089019A (es) 2009-02-27

Family

ID=38686795

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008009019A ECSP089019A (es) 2006-06-02 2008-12-29 Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa

Country Status (22)

Country Link
US (1) US20080021056A1 (es)
EP (2) EP2038280A2 (es)
JP (1) JP2009539773A (es)
KR (1) KR20090015159A (es)
CN (2) CN101501032B (es)
AR (1) AR061161A1 (es)
AU (1) AU2007256860A1 (es)
BR (1) BRPI0712123A2 (es)
CA (1) CA2651550A1 (es)
EA (1) EA200870577A1 (es)
EC (1) ECSP089019A (es)
IL (1) IL195078A0 (es)
MA (1) MA30532B1 (es)
MX (1) MX2008014947A (es)
MY (1) MY169274A (es)
NO (1) NO20085323L (es)
NZ (1) NZ572885A (es)
PE (1) PE20080988A1 (es)
SG (1) SG172629A1 (es)
TW (1) TW200813054A (es)
UY (1) UY30377A1 (es)
WO (1) WO2007143523A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009414A (es) 2006-01-20 2008-10-01 Schering Corp Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa.
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
NZ582039A (en) 2007-05-25 2012-02-24 Elan Pharm Inc Pyrazolopyrrolidines as inhibitors of gamma secretase
CN101754960A (zh) * 2007-07-05 2010-06-23 先灵公司 四氢吡喃并色烯γ-分泌酶抑制剂
CA2693216A1 (en) * 2007-07-17 2009-01-22 Schering Corporation Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
WO2010028213A2 (en) * 2008-09-05 2010-03-11 Elan Pharmaceuticals, Inc. N-sulfonamido polycyclic pyrazolyl compounds
CA2756064A1 (en) * 2009-03-25 2010-09-30 Elan Pharmaceuticals, Inc. Process for the production of fused, tricyclic sulfonamides
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
US9023767B2 (en) * 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
US9632088B2 (en) 2010-09-07 2017-04-25 Memorial Sloan-Kettering Cancer Center Methods and compositions for gamma-secretase assay
US10319527B2 (en) * 2017-04-04 2019-06-11 Samsung Electro-Mechanics Co., Ltd. Multilayer capacitor
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN110526913B (zh) * 2019-08-30 2022-04-29 中国药科大学 一种抗凝药物阿哌沙班相关物质的制备方法
CN110885329B (zh) * 2019-12-16 2020-12-15 诚达药业股份有限公司 一种1,7-萘啶衍生物的合成方法
WO2021203014A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
EP4126863A1 (en) 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 1 h-pyrazolo[4,3-g]isoquinoline and 1 h-pyrazolo[4,3-g]quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
CN114853707B (zh) * 2022-06-13 2024-01-26 上饶师范学院 一种合成二氟氢甲基化2,3-二氢苯并吡喃-4-酮衍生物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
JPH0977752A (ja) * 1995-09-12 1997-03-25 Kao Corp Ｎ−無置換イソオキサゾリジンの製造法
GB9720899D0 (en) 1997-10-01 1997-12-03 Pharmacia & Upjohn Spa Condensed heterocyclic compounds
CN1304390C (zh) * 2001-08-03 2007-03-14 先灵公司 新颖的γ—分泌酶抑制剂
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
JP2006151810A (ja) * 2002-12-26 2006-06-15 Daiichi Asubio Pharma Co Ltd ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
US20060264380A1 (en) 2003-07-21 2006-11-23 Mats Hellstrom Compounds and Methods for Promoting Angiogenesis
EP1758884A2 (en) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US7563793B2 (en) * 2004-12-20 2009-07-21 Wyeth Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents

Also Published As

Publication number Publication date
CN101501032A (zh) 2009-08-05
CA2651550A1 (en) 2007-12-13
PE20080988A1 (es) 2008-08-15
AR061161A1 (es) 2008-08-06
WO2007143523A8 (en) 2008-01-31
US20080021056A1 (en) 2008-01-24
CN101501032B (zh) 2012-10-10
TW200813054A (en) 2008-03-16
NO20085323L (no) 2009-02-24
MY169274A (en) 2019-03-21
JP2009539773A (ja) 2009-11-19
WO2007143523A3 (en) 2008-06-12
EP2450358A1 (en) 2012-05-09
MA30532B1 (fr) 2009-06-01
CN102850349A (zh) 2013-01-02
BRPI0712123A2 (pt) 2012-07-10
IL195078A0 (en) 2009-08-03
SG172629A1 (en) 2011-07-28
KR20090015159A (ko) 2009-02-11
NZ572885A (en) 2012-02-24
AU2007256860A1 (en) 2007-12-13
WO2007143523A2 (en) 2007-12-13
EP2038280A2 (en) 2009-03-25
EA200870577A1 (ru) 2009-06-30
UY30377A1 (es) 2008-01-02
MX2008014947A (es) 2008-12-10

Similar Documents

Publication Publication Date Title
ECSP10010245A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
CR11819A (es) Compuestos de isoindolina 5-sustituidos
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
NI200900021A (es) Inhibidor de quinasa
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
CO6511251A2 (es) Compuestos quimicos
NI200700319A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento.
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735